Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.

Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial. J Geriatr Psychiatry Neurol. 1990 Jan-Mar; 3(1):13-6.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.